M&R Capital Management’s Sage Therapeutics SAGE Stock Holding History

M&R Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-300	Closed	-$54K	–	509
2019 Q2	$54K	Hold	300	–	–	0.01%	267
2019 Q1	$50K	Hold	300	–	–	0.01%	277
2018 Q4	$28K	Buy	+300	New	+$34.3K	0.01%	322

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

M&R Capital Management's SAGE Position: Q3 2019 in Review

M&R Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 300 shares — an estimated $54K sold.

M&R Capital Management first reported a position in SAGE in Q4 2018 and held it in 3 quarters. The position peaked at $54K in Q2 2019. 284 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

M&R Capital Management reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
M&R Capital Management sold 300 Sage Therapeutics shares in Q3 2019, an estimated $54K.
M&R Capital Management first reported a position in Sage Therapeutics in Q4 2018 and held it in 3 quarters.
M&R Capital Management's Sage Therapeutics position peaked at $54K in Q2 2019.
284 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on M&R Capital Management's 13F filing for Q3 2019, filed 2 Oct 2019.